Citius Oncology, Inc.

CTOR · Nasdaq

Citius Oncology, Inc. (CTOR) is a Drug manufacturers general company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Citius Oncology, Inc. in 2026. The next earnings report is expected on December 17, 2026.

Earnings calendar

Next earnings date

17 Dec 2026

In 119 days

EPS estimate

-0.19

Revenue estimate

5.8M

Past earnings

Date	EPS actual	Revenue actual	1d	5d	30d
14 Aug 2026	-0.08 (-14.3%) estimate -0.07	1.5M (-40.2%) estimate 2.5M	+2.37%	-2.41%	+4.37%
15 May 2026	-0.27 (-2,600.0%) estimate -0.01	1.7M (-76.2%) estimate 7.0M	+2.37%	-2.41%	+4.37%
13 Feb 2026	-0.06 (-50.0%) estimate -0.04	3.9M (-9.8%) estimate 4.4M	+2.37%	-2.41%	+4.37%

14 Aug 2026

EPS actual

-0.08 (-14.3%)

estimate -0.07

Revenue actual

1.5M (-40.2%)

estimate 2.5M

Price reaction

+2.37%

-2.41%

30d

+4.37%

15 May 2026

EPS actual

-0.27 (-2,600.0%)

estimate -0.01

Revenue actual

1.7M (-76.2%)

estimate 7.0M

Price reaction

+2.37%

-2.41%

30d

+4.37%

13 Feb 2026

EPS actual

-0.06 (-50.0%)

estimate -0.04

Revenue actual

3.9M (-9.8%)

estimate 4.4M

Price reaction

+2.37%

-2.41%

30d

+4.37%

Beat Miss usd

Latest earnings analysis

Citius Oncology, Inc. missed consensus estimates in its latest earnings report, with EPS of -$0.08 versus an estimate of -$0.07 and revenue of $1.49 million falling 40.2% short of expectations. Both EPS and revenue also came in below expectations in the previous report.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Drug manufacturers general
Country: United States
Exchange: Nasdaq
CEO: Leonard L. Mazur
IPO date: 08 Dec 2022
ISIN: US17331Y1091
Website: citiusonc.com/overview/default.aspx

Frequently asked questions

When does Citius Oncology, Inc. (CTOR) next report earnings?

Citius Oncology, Inc. (CTOR) is scheduled to report earnings on December 17, 2026.

What was Citius Oncology, Inc.'s most recent earnings date?

Citius Oncology, Inc. (CTOR) last reported earnings on August 14, 2026.

Where is Citius Oncology, Inc. stock listed?

Citius Oncology, Inc. (CTOR) is listed on Nasdaq.